SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla reached a new all-time high, fueling community discussions around its robotaxi strategy and battery expansion plans in Europe. Bullish sentiment appears strong, with some traders eyeing the $500 level and beyond, while others caution about stretched valuations and potential pullbacks. Discussions also include the company's long-term growth potential and competition in the EV market.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's potential $10B investment from OpenAI to utilize its AI chips is a hot topic, fueling discussions about the data center sector and analysts' target prices. The community is analyzing Amazon's infrastructure and AWS re-acceleration, while some express concerns about the investment's impact and potential market reactions, viewing it as an AI "circle jerk."

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to new highs, driven by speculation around supply constraints and increased industrial demand, particularly for AI data centers. The community is discussing potential for further gains, with some pointing to historical patterns and a possible shift in market dynamics as financial institutions adjust their positions. Concerns about market manipulation and the impact of COMEX margin hikes are also circulating among investors.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its recent merger and focus on robotics, with community members comparing it to past high-flying stocks. The stock's low float and high short interest are fueling speculation of a potential short squeeze, with many retail investors encouraging others to hold firm. Community members are actively discussing price targets and strategies to counter short sellers.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as anticipation builds around potential cannabis rescheduling, fueled by reports of a possible executive order. The community is buzzing over the implications of rescheduling, particularly the potential for tax relief and increased institutional investment. Traders are closely watching for official confirmation and the resulting impact on US cannabis companies.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its community-driven approach and its positioning as a culture coin on the Solana network, drawing comparisons to Bitcoin. Discussions also emphasize the potential benefits of cannabis and hemp within the biotech and environmental sectors, tying these broader themes to the token's future prospects. The community emphasizes the coins unique culture, building, creativity, and the plant's potential for healing.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending as traders discuss its potential breakout, noting that it is coiling under resistance. Community members are watching for volume expansion to confirm a fresh trend in this mid-cap laser tech company. Some also point to possible defense contracts, such as the "Golden Dome", as a catalyst.

B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

B. Riley Financial Inc

B. Riley Financial is trending as investors digest the company's overdue Q2 report, which revealed a swing to profitability and adherence to Nasdaq's listing compliance deadline, easing delisting fears. Community discussions revolve around the potential for a short squeeze, fueled by high short interest and the company's low float, while some express concerns about debt and management issues. Overall, the report is being viewed as a positive step toward addressing fundamental issues.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as silver prices test new highs, generating excitement about the company's potential profitability; the community is discussing the disconnect between silver's rise and AG's stock performance, as well as potential manipulation. Some are pointing to AG's long-term potential given the bullish outlook for silver and possible acquisitions.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation surrounding potential rescheduling of cannabis, driven by reports of an upcoming executive order from President Trump, which has fueled significant trading volume. The community is closely watching for official confirmation, with many anticipating substantial gains if the rescheduling occurs, while some caution against potential pullbacks or dilution. Discussions range from short-term trading strategies to long-term investment perspectives, reflecting high interest in the cannabis sector's potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

ETF Areas to Buy on Fed Cuts and Trade Truce Optimism

Fed turns dovish and trade tensions ease. Amid this scenario, tech & growth ETFs could soar along with some other areas. Watch SMH, QQQ, SPYG & IWO as markets may be up for a renewed rally.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

Equity

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

Tvardi Therapeutics (TVRD) on Monday said that its TTI-101, being evaluated in idiopathic pulmonary fibrosis (IPF), showed no benefit over placebo in a mid-stage trial.The trial was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function in patients with IPF. Idiopathic Pulmonary Fibrosis is a progressive lung disease where lung tissue thickens and scars, making it difficult to breathe. However, the study did not meet its goals, and no statistically significant differences between placebo and treatment arms were observed after a preliminary review of exploratory efficacy, it said.Shares of the company plummeted 87% in Monday’s pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TVRD">TVRD stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.Tvardi said that preliminary data showed that patients’ baseline characteristics were mostly similar across treatment arms, including those who received the two doses of TTI-101 or those who received a placebo in the trial. Furthermore, lower discontinuation rates were observed in the placebo group compared to the therapy-treated arms, it added.The company also noted that patients who demonstrated changes in the lung’s Forced Vital Capacity (FVC) were 41% for the placebo, and 39% and 44% for the 400mg and 800mg TTI-101-treated arms, respectively.“In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study. The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” CEO Imran Alibhai said.The CEO added that the company is now conducting additional analyses to understand the trial findings further. He also noted that the company is on track to report preliminary data from the mid-stage trial of TTI-101 in hepatocellular carcinoma.TVRD stock has risen about 127% this year and more than quadrupled over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-commences-production-ramp-up-at-shanghai-gigafactory/ch6SiqpR3kW">Tesla Reportedly Commences Production Ramp-Up At Its Shanghai Gigafactory</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?

The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review of exploratory efficacy. 

SoundHound AI, Inc.(SOUN) on Wednesday said it has teamed up with Apivia Courtage, part of the AEMA Group, to bring advanced AI agents into the insurer’s contact centers using SoundHound’s Amelia 7 platform.Under this collaboration, Apivia Courtage will roll out Amelia 7, an AI agent system designed to act autonomously, as a key component of its digital overhaul strategy, building on the success with SoundHound’s platform, which resulted in a 20% productivity boost.<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI stock</a> traded over 8% higher on Wednesday afternoon. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘normal message volume levels.<figure class="image"><img style="aspect-ratio:925/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_08_130638_png_e64e4f8927.webp" alt="SOUN’s Sentiment Meter and Message Volume as of 12:45 p.m. ET on Oct. 8, 2025 | Source: Stocktwits" width="925" height="100"><figcaption>SOUN’s Sentiment Meter and Message Volume as of 12:45 p.m. ET on Oct. 8, 2025 | Source: Stocktwits</figcaption></figure>The stock saw a 161% increase in user message count in the last month, as per platform data. A Stocktwits user expressed confidence in the partnership, stating that the company is a “huge player” in France.<stembedurl>https://stocktwits.com/Ibiolegends/message/631509252</stembedurl>Amelia’s architecture blends large language models’ reasoning and planning with structured rule‑driven workflows. It also supports escalation to humans when needed. The AI agents operate across multiple channels, including voice, chat, and text.With Amelia 7’s “agentic” capabilities, Apivia aims to let customers self‑serve on more types of inquiries without human intervention. The AI agents will interpret multiple intents in a single interaction, carry out tasks like identity verification via one-time passwords, answer policy questions, update contact details, compute the financial impact of contract changes, and initiate quotes or book meetings with advisors.Since 2023, the two companies have worked together to integrate AI agents alongside human staff at Apivia’s call centers. SoundHound AI stock has gained over 317% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-hits-all-time-high-after-nvidia-ceo-jensen-huang-calls-offering-10-percent-stake-to-open-ai-clever/ch6EpkDR30b">AMD Hits All-Time High After Nvidia CEO Jensen Huang Calls Offering 10% Stake To OpenAI ‘Clever’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Amelia logo is being displayed on a mobile phone screen in front of a monitor displaying SoundHoundAI logo in Ankara, Turkiye on August 27, 2024. 

SoundHound, Apivia Deploy Agentic AI For Insurance Contact Centers: Retail Sentiment Jumps

Under the partnership, Apivia Courtage will roll out Amelia 7, an AI agent system designed to act autonomously, building on earlier success where SoundHound’s platform boosted productivity by 20%.

Small-Cap Wins in Q3: Top-Performing ETFs in Focus 

Small caps staged a comeback in Q3, with ETFs like FESM, RZV, FYX, VTWV, JSML, IWO topping gains. While there are certain tariff risks, the Fed's rate cut potential is a plus. 

SoundHound AI Inc. (SOUN) stock was in the spotlight on Monday morning after the shares received an upgrade from Ladenburg Thalmann, which raised its rating to ‘Buy’ from ‘Neutral’ and raised the price target to $16 from $9.&nbsp;The brokerage cited strong second-quarter (Q2) results and successful execution on large enterprise deals as key reasons for its upgrade, as per TheFly.&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound AI stock</a> shot up over 13% on Monday morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<figure class="image"><img style="aspect-ratio:955/110;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_095242_png_df04a03eb4.webp" alt="SOUN’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="955" height="110"><figcaption>SOUN’s Sentiment Meter and Message Volume as of 09:45 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 176% increase in user message count over 24 hours, as of Monday morning. A Stocktwits user said the business has ‘great demand’.<stembedurl>https://stocktwits.com/Tekoa/message/624580522</stembedurl>Another user commended the Q2 earnings print.<stembedurl>https://stocktwits.com/paaps/message/624567480</stembedurl>Ladenburg sees sales growth momentum as justifying its increased spending levels. The brokerage remains optimistic about the opportunity in voice-based artificial intelligence, identifying it as one of the most promising early-use cases in the AI space.&nbsp;The firm believes SoundHound’s products cater to businesses that want to integrate AI-driven voice features into their operations.The company’s Q2 revenue jumped 217% year-on-year (YoY) to $42.7 million, beating the analysts’ consensus estimate of $32.88 million, as per Fiscal AI data. The adjusted loss per share of $0.03 came in wider than the consensus estimate of a loss of $0.01.The company raised its FY2025 revenue guidance to a range of $160 million and $178 million. On August 7, SoundHound launched Vision AI, a visual recognition engine built directly into its voice-centric platform.SoundHound AI stock has lost over 24% year-to-date and has gained over 190% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/black-monday-for-monday-dot-com-stock/chruzItRdeT">Black Monday For Monday.Com Stock? Here’s What Co-CEO Roy Mann Said About Google Algorithm Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Binary code displayed on a laptop screen displayed on a laptop screen and SoundHound AI logo displayed on a phone screen are seen in this illustration photo taken in Krakow, Poland on August 8, 2025. 

SoundHound Stock Surged 13% Today – And Ladenburg Thalmann Has A New Price Target 

The firm cited strong second-quarter results and successful execution on large enterprise deals as key reasons for the upgrade.

SoundHound stock was the top-trending equity ticker on Stocktwits late Thursday as retail investors reacted to the conversational artificial intelligence (AI) company announcing a beat-and-raise quarter.Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SOUN">SoundHound stock</a> turned to ‘extremely bullish’ (88/100) by late Thursday from ‘neutral’ a day ago. The message volume also picked up pace to ‘extremely high’ levels.&nbsp;The 24-hour message volume change leading up to late Thursday was about 500%.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_07_at_10_15_05_PM_png_18725d4ece.webp" alt="Screenshot 2025-08-07 at 10.15.05 PM.png" width="618" height="54"><figcaption>SOUN sentiment and message volume as of 10:15 p.m. ET, Aug. 7 | source: Stocktwits</figcaption></figure>Santa Clara, California-based SoundHound reported a loss of $0.03 per share on an adjusted basis for the second quarter of the fiscal year 2025, narrower than the year-ago loss of $0.04 and the Factset-compiled consensus of $0.05 per share.Revenue climbed 217% year-over-year to $42.68 million, sharply higher than the $32.9-million consensus estimate.Co-founder and CEO Keyvan Mohajer said, “In SoundHound’s strongest ever quarter, many of our previous strategic moves delivered high-impact results with growth across every business unit.”“We realized significant new wins as well as cross-sell deals, demonstrating the incredible opportunity we predicted with our 2024 acquisitions.”SoundHound ended the quarter with cash and cash equivalents of $230 million as of June 30 and boasted of no debt on its balance sheet.The company raised its full-year revenue outlook to a range of $160 million to $178 million from a range of $157 million to $177 million.Underlining the massive potential for conversational AI,&nbsp;Mark Zuckerberg’s Meta&nbsp;Platforms Inc.&nbsp;made its second voice AI startup acquisition, WaveForms, according to a report by The Information, just a month after purchasing PlayAI.Commenting on Stocktwits, a bullish watcher&nbsp;noted that a majority of the volume in SoundHound stock over the past week was from dark pool or off-exchange transactions. They also noted that the short interest was high,&nbsp;which they considered a positive for the underlying stock.<stembedurl>https://stocktwits.com/notihimself/message/624253898</stembedurl>The short interest in the stock is currently at 30.32%, according to Koyfing, and it has remained above this level since late May.Another user&nbsp;considered the stock price to be too low, noting that it was trading at double the current levels at the start of the year and that the earnings report indicated the company was performing well.<stembedurl>https://stocktwits.com/DakotaDan1/message/624252035</stembedurl>SoundHound stock has grossly underperformed the broader market, having lost 46% this year. In overnight trading, the stock was up over 14%, and if&nbsp;gains carry over into Friday’s session, it&nbsp;would mark its best session since late May, according to Koyfin data.The Koyfin-compiled average analysts’ price target for the stock is $11.81, implying upside potential of over 10%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-stock-marks-worst-day-in-25-years-as-weight-loss-pill-data-disappoints-analysts-divided-but-retail-bets-on-rebound/chrVvOxRd3V">Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound</a>

SoundHound Retail Traders Brace For More Stock Gains After Voice AI Player Reports ‘Strongest-Ever Quarter’

The company’s Q2 revenue soared 217% year-over-year to $42.68 million, sharply higher than the $32.9-million consensus estimate.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 Growth ETF

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

IWO
iShares Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWO News

IWOiShares Russell 2000 Growth ETF